Human ACE and bradykinin B 2 receptors form a complex at the plasma membrane
- 1 November 2006
- journal article
- research article
- Published by Wiley in The FASEB Journal
- Vol. 20 (13), 2261-2270
- https://doi.org/10.1096/fj.06-6113com
Abstract
To investigate how angiotensin I-converting enzyme (ACE) inhibitors enhance the actions of bradykinin (BK) on B2 receptors independent of blocking BK inactivation, we expressed human somatic ACE and B2 receptors in CHO cells. Bradykinin and its ACE-resistant analog were the receptor agonists. B2 fused with green fluorescent protein (GFP) and ACE were coprecipitated with antisera to GFP or ACE shown in Western blots. Immunohistochemistry of fixed cells localized ACE by red color and B2-GFP by green. Yellow on plasma membranes of coexpressing cells also indicated enzyme-receptor complex formation. Using ACE-fused cyan fluorescent protein donor and B2-fused yellow fluorescent protein (YFP) acceptor, we registered fluorescence resonance energy transfer (FRET) by the enhanced fluorescence of donor on acceptor photobleaching, establishing close (within 10 nm) positions of B2 receptors and ACE. Bradykinin stimulation cointernalized ACE and B2 receptors. We expressed ACE fused to N terminus of B2 receptors, anchoring only receptors to plasma membranes. Here, in contrast to cells, where both ACE and B2 receptors are separately anchored, ACE inhibitors neither enhance activation of chimeric B2 nor resensitize desensitized B2 receptors. Heterodimer formation between ACE and B2 receptors can be a mechanism for ACE inhibitors to augment kinin activity at cellular level.Keywords
Funding Information
- National Institutes of Health (HL36473, HL68580)
This publication has 48 references indexed in Scilit:
- Hydrolysis of Angiotensin Peptides by Human Angiotensin I–Converting Enzyme and the Resensitization of B 2 Kinin ReceptorsHypertension, 2005
- Angiotensin I-Converting Enzyme Inhibitors Block Protein Kinase Cϵ by Activating Bradykinin B1 Receptors in Human Endothelial CellsJournal of Pharmacology and Experimental Therapeutics, 2005
- Effect of angiotensin-converting enzyme or vasopeptidase inhibition on ventricular size and function in patients with heart failure: The Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE) echocardiographic studyAmerican Heart Journal, 2005
- Potentiation of bradykinin actions by analogues of the bradykinin potentiating nonapeptide BPP9αPeptides, 2005
- Signaling via the Angiotensin-Converting Enzyme Enhances the Expression of Cyclooxygenase-2 in Endothelial CellsHypertension, 2005
- Novel Mode of Action of Angiotensin I Converting Enzyme InhibitorsPublished by Elsevier ,2002
- Neprilysin Inhibitors Potentiate Effects of Bradykinin on B2 ReceptorHypertension, 2002
- Enhancement of Bradykinin and Resensitization of Its B 2 ReceptorHypertension, 1999
- Human Converting EnzymeClinical and Experimental Hypertension. Part A: Theory and Practice, 1983
- Angiotensin converting enzyme inhibition in patients with congestive heart failure.Circulation, 1978